# Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

> **NCT01060384** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 46 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** ofatumumab

## Key facts

- **NCT ID:** NCT01060384
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03-29
- **Primary completion:** 2016-10-25
- **Final completion:** 2018-01-01
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-10-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01060384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01060384, "Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01060384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*